Difference between revisions of "Team:BostonU"
| Line 42: | Line 42: | ||
background-size: cover !important; | background-size: cover !important; | ||
z-index: -100; | z-index: -100; | ||
| + | display: none; | ||
} | } | ||
#mybody { | #mybody { | ||
| Line 66: | Line 67: | ||
list-style-type: none; | list-style-type: none; | ||
margin-top: 5%; | margin-top: 5%; | ||
| − | margin-right: | + | margin-right: 5%; |
padding: 0; | padding: 0; | ||
position: relative; | position: relative; | ||
| Line 282: | Line 283: | ||
<div id="myfooterR"><a>SAY HI</a><a href="https://twitter.com/BostonU_iGEM_WL"><img src="https://static.igem.org/mediawiki/2017/2/21/T--BostonU--prettysureweareallowedtouploadthis.svg"></img></a> <a href="mailto:bu.igemwl2017@gmail.com"><img style="height: 19px;" src="https://static.igem.org/mediawiki/2017/c/ca/T--BostonU--MailTo.svg"></img></a> </div> | <div id="myfooterR"><a>SAY HI</a><a href="https://twitter.com/BostonU_iGEM_WL"><img src="https://static.igem.org/mediawiki/2017/2/21/T--BostonU--prettysureweareallowedtouploadthis.svg"></img></a> <a href="mailto:bu.igemwl2017@gmail.com"><img style="height: 19px;" src="https://static.igem.org/mediawiki/2017/c/ca/T--BostonU--MailTo.svg"></img></a> </div> | ||
</div> | </div> | ||
| − | <div class="fade-in-div"> <a class="wordmark" href="https://2017.igem.org/Team:BostonU"><img src="https://static.igem.org/mediawiki/2017/ | + | <div class="fade-in-div"> <a class="wordmark" href="https://2017.igem.org/Team:BostonU"><img src="https://static.igem.org/mediawiki/2017/f/f2/T--BostonU--RedGrey.svg"></img></a> |
<section id="fade-in-wrapper" class="link-slideup body-type"> | <section id="fade-in-wrapper" class="link-slideup body-type"> | ||
<p>We explore the use of de novo designed riboriboregulators known as <a href="#">toehold switches</a> to drive recombinase-based logic in <a href="#">cell-free TX-TL systems.</a> We anticipate applications in <a href="#">point-of-care diagnostic technologies</a> such as those for Zika and Ebola developed by the Collins group at MIT, targeted at diseases with RNA profiles that are more computationally demanding, such as cancer.</p> | <p>We explore the use of de novo designed riboriboregulators known as <a href="#">toehold switches</a> to drive recombinase-based logic in <a href="#">cell-free TX-TL systems.</a> We anticipate applications in <a href="#">point-of-care diagnostic technologies</a> such as those for Zika and Ebola developed by the Collins group at MIT, targeted at diseases with RNA profiles that are more computationally demanding, such as cancer.</p> | ||
| Line 349: | Line 350: | ||
}); | }); | ||
}); | }); | ||
| + | </script> | ||
| + | <script> /* THIS MAKES BODY CONTENT OF THE PAGE FADE IN */ | ||
| + | $(document).ready(function () { | ||
| + | $('body').fadeIn(1000); | ||
| + | }); | ||
</script> | </script> | ||
</body> | </body> | ||
</html> | </html> | ||
Revision as of 20:20, 7 September 2017
